Rural Appalachian Research Center
Hazard, Kentucky, 41071, United States
NCT Number: NCT01840722
The overall aim of this study is to reduce risk behaviors and increase health and behavioral health service utilization among disadvantaged, drug-using rural women at high risk for HIV and HCV. This project has potential to make a significant contribution to science by providing knowledge about the health, risk behaviors, and service utilization of a vulnerable and understudied group of women during a time of emerging and significant public health risk in a rural Appalachian setting. Successful completion of the aims of this project will advance the delivery of a low-cost, potentially high impact intervention with implications for a number of other real world settings (such as criminal justice venues) where other disadvantaged high-risk drug users can be identified and targeted for intervention.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Hazard, Kentucky, 41071, United States
Specific Aim 1: Compare the effectiveness of an evidence-based HIV risk reduction intervention (MI-HIV) to HIV Education (NIDA Standard) in reducing sex risk behaviors, injection practices, and drug use among a culturally unique sample of disadvantaged, drug-using rural women at high-risk for HIV and HCV. This aim will be accomplished through the random selection of high-risk rural women drug users from rural jails, screening and assessment for high-risk behavior, and random assignment to the HIV-Ed or MI-HIV intervention conditions. Follow-up interviews at 3, 6, and 12 months in the community post-release will examine changes in high-risk behavior. It is expected that MI-HIV participants will report significantly greater reductions in risky injection drug use practices, other drug use, and sex risk behaviors than women who participate in the HIV-Ed condition.
Specific Aim 2: Examine MI-HIV Intervention engagement as a predictor of community health and behavioral health service utilization (including drug treatment and mental health) at follow-up among disadvantaged, drug-using rural women at high risk for HIV and HCV. This aim will focus on community service utilization during the follow-up period by the intervention and education comparison group, and how health and behavioral health service utilization relates to patterns of HIV/HCV risk behavior. It is expected that MI-HIV participants will utilize more services due to increased motivation for treatment and treatment planning following the brief intervention.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
Other names: Motivational Interviewing for HIV Risk Reduction, Portland Women's Health Program
Time frame: 6 months
Had unprotected sex with a casual partner or when trading sex for money, drugs, etc in the past 6 months
Time frame: 6 months
Sex with a Partner in Exchange for Money, Drugs, Food, Shelter, Transportation, etc. in the past 6 months
Time frame: 6 months
Is currently being treated for a physical or mental health problem OR has been in a substance use treatment program in the last 6 months
Michele Staton
Other
Acronym: WISH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01976715
AIDS Virus, Acquired Immune Deficiency Syndrome Virus
Bethesda, Maryland, United States
View Trial DetailsNCT02266992
Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome
Sheffield, South Yorkshire, United Kingdom
View Trial DetailsNCT01766076
Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome
View Trial DetailsNCT04048850
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Chicago, Illinois, United States
View Trial Details